Actively Recruiting
Folfox+Irinotecan+Chemort In Esophageal Cancer
Led by Massachusetts General Hospital · Updated on 2025-11-14
40
Participants Needed
3
Research Sites
335 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
I
Ipsen
Collaborating Sponsor
AI-Summary
What this Trial Is About
In this research study, is studying how Liposomal Irinotecan in combination with the standard of care interventions FOLFOX, carboplatin paclitaxel, and radiation therapy affect gastroesophageal junction or esophagogastric cancer This research study involves the following study intervention: \- Liposomal irinotecan
CONDITIONS
Official Title
Folfox+Irinotecan+Chemort In Esophageal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed T3/4 or N+ gastroesophageal junction or esophagogastric cancer
- Age 18 years or older with no upper age limit
- ECOG performance status of 0 or 1
- Life expectancy greater than 3 months
- Adequate organ and marrow function including neutrophils, platelets, bilirubin, liver enzymes, and kidney function
- Agreement to use effective contraception during and for 30 days after study treatment if of childbearing potential
- Negative pregnancy test for females of childbearing potential
- Ability to understand and willingness to sign informed consent
You will not qualify if you...
- Evidence of metastatic disease outside the radiation area
- Previous chemotherapy, targeted therapy, or radiation for esophagogastric cancer
- Treatment of other invasive cancers with high recurrence risk within past 5 years
- Use of any investigational agents within 4 weeks before study start
- Serious systemic disorders such as significant cardiac or pulmonary disease or recent heart attack
- History of uncontrolled seizures, CNS disorders, or psychiatric disability affecting consent or compliance
- Pregnant or breastfeeding women
- Major surgery within 4 weeks before study start without full recovery
- Concurrent use of cimetidine
- Known uncontrolled bleeding disorders
- Prior systemic fluoropyrimidine therapy within 6 months unless adjuvant
- Known allergy to 5-fluorouracil, irinotecan, oxaliplatin, or related compounds
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
Actively Recruiting
2
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Not Yet Recruiting
3
Massachusetts General Hospital at Newton Wellesley Hospital
Newton, Massachusetts, United States, 02462
Actively Recruiting
Research Team
J
Jennifer Wo, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here